NEWS and INFORMATION
The following posts and articles are for information only regarding advancements in our technology and business as well as relevant articles on the state of research and important voices of authority in the medical community.
Cognos Therapeutics, Inc. To Be Publicly Listed On Nasdaq
Cognos Therapeutics, Inc. announced a definitive business combination agreement with Nocturne Acquisition Corporation to allow it to be publicly listed on Nasdaq.
Labroot’s Report Focuses on the Need To Develop Better Methods To Deliver Therapeutics to the Brain
Cognos Therapeutics, Inc. announced a definitive business combination agreement with Nocturne Acquisition Corporation to allow it to be publicly listed on Nasdaq.
Cognos Co-Founder and CIO Josh Shachar Discusses The Evolution of the Cognos Vision
Josh Shachar shares his vision for the impact Cognos Therapeutics’ technology will have in the current exploding junction between innovation and communication.
Cognos Engages Maxim Group for Investment Banking and Financial Advisory Services
Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC to provide financial advisory and investment banking services.
Cognos Announces Addition of New Clean Room To Expand Its Development Capabilites.
Cognos’ new cleanroom expands its ability to bring prototype development of its next-gen implantable pump technology in-house.
Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant
Dr. Susan Alpert, MD, PhD, has been named, Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory experts.
Cognos’ SINNAIS Smart Implantable Pump to Improve CAR T Cell Efficacy in Solid tumors
Cognos Therapeutics believes its SINNAIS implantable pump can increase efficacy of CAR T therapies for the treatment of leukemia.
Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.
Cognos Therapeutics plans to conduct a 20-patient human clinical trial for direct delivery of Herceptin using the Sinnais implantable pump.
Dr. Francis Ali-Osman
Dr. Francis Ali-Osman speaks at the Hancock Symposium at Westminster Collage on the state of cancer research and treatment.
FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.
Cognos Therapeutics’ Sinnais drug delivery technology is poised to meet the need for Companion Diagnostic modalities.